How to Make the Right Choice of Proton Pump Inhibitor for Patients with Gastroesophageal Reflux Disease?

Аim: to analyze the main pharmacokinetic properties of proton pump inhibitors (PPIs) and their significance in the treatment of gastroesophageal reflux disease (GERD).Key points. Pantoprazole has a high bioavailability, the absolute bioavailability of pantoprazole at a dose of 40 mg is 77 % from the...

Full description

Saved in:
Bibliographic Details
Main Author: Yu. V. Evsyutina
Format: Article
Language:Russian
Published: Gastro LLC 2023-06-01
Series:Российский журнал гастроэнтерологии, гепатологии, колопроктологии
Subjects:
Online Access:https://www.gastro-j.ru/jour/article/view/770
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1823860064451035136
author Yu. V. Evsyutina
author_facet Yu. V. Evsyutina
author_sort Yu. V. Evsyutina
collection DOAJ
description Аim: to analyze the main pharmacokinetic properties of proton pump inhibitors (PPIs) and their significance in the treatment of gastroesophageal reflux disease (GERD).Key points. Pantoprazole has a high bioavailability, the absolute bioavailability of pantoprazole at a dose of 40 mg is 77 % from the first dose and does not change with repeated use. Pantoprazole shows a faster onset of action than omeprazole. Simultaneous food intake does not change the bioavailability of pantoprazole. Suppression of hydrochloric acid production while taking pantoprazole accompanies by the achievement of endoscopic remission of GERD by day 28 in 91 % of patients with reflux esophagitis and by day 56 in all patients in the PANSTAR studies. Pantoprazole has little effect on CYP2C19 compared to other PPIs, minimizing the risk of drug-drug interactions. Pantoprazole is the most pH-selective PPI, which determines the specificity of action only in the parietal cells of the stomach and the greatest safety of long-term use in patients with comorbid pathology.Conclusion. PPIs form the basis of the therapy of acid-dependent diseases, and, in particular, gastroesophageal reflux disease. Pantoprazole is distinguished from other PPIs by its persistent high bioavailability, long-term antisecretory effect, and very low affinity for cytochrome P450.
format Article
id doaj-art-a20f0309b37648519d7ec766468b0fd1
institution Kabale University
issn 1382-4376
2658-6673
language Russian
publishDate 2023-06-01
publisher Gastro LLC
record_format Article
series Российский журнал гастроэнтерологии, гепатологии, колопроктологии
spelling doaj-art-a20f0309b37648519d7ec766468b0fd12025-02-10T16:14:38ZrusGastro LLCРоссийский журнал гастроэнтерологии, гепатологии, колопроктологии1382-43762658-66732023-06-01331687610.22416/1382-4376-2023-33-1-68-76526How to Make the Right Choice of Proton Pump Inhibitor for Patients with Gastroesophageal Reflux Disease?Yu. V. Evsyutina0Centre hospitalier universitaire vaudoisАim: to analyze the main pharmacokinetic properties of proton pump inhibitors (PPIs) and their significance in the treatment of gastroesophageal reflux disease (GERD).Key points. Pantoprazole has a high bioavailability, the absolute bioavailability of pantoprazole at a dose of 40 mg is 77 % from the first dose and does not change with repeated use. Pantoprazole shows a faster onset of action than omeprazole. Simultaneous food intake does not change the bioavailability of pantoprazole. Suppression of hydrochloric acid production while taking pantoprazole accompanies by the achievement of endoscopic remission of GERD by day 28 in 91 % of patients with reflux esophagitis and by day 56 in all patients in the PANSTAR studies. Pantoprazole has little effect on CYP2C19 compared to other PPIs, minimizing the risk of drug-drug interactions. Pantoprazole is the most pH-selective PPI, which determines the specificity of action only in the parietal cells of the stomach and the greatest safety of long-term use in patients with comorbid pathology.Conclusion. PPIs form the basis of the therapy of acid-dependent diseases, and, in particular, gastroesophageal reflux disease. Pantoprazole is distinguished from other PPIs by its persistent high bioavailability, long-term antisecretory effect, and very low affinity for cytochrome P450.https://www.gastro-j.ru/jour/article/view/770gastroesophageal reflux diseaseparietal cellproton pump inhibitorspantoprazolebioavailabilitydrug-drug interactions
spellingShingle Yu. V. Evsyutina
How to Make the Right Choice of Proton Pump Inhibitor for Patients with Gastroesophageal Reflux Disease?
Российский журнал гастроэнтерологии, гепатологии, колопроктологии
gastroesophageal reflux disease
parietal cell
proton pump inhibitors
pantoprazole
bioavailability
drug-drug interactions
title How to Make the Right Choice of Proton Pump Inhibitor for Patients with Gastroesophageal Reflux Disease?
title_full How to Make the Right Choice of Proton Pump Inhibitor for Patients with Gastroesophageal Reflux Disease?
title_fullStr How to Make the Right Choice of Proton Pump Inhibitor for Patients with Gastroesophageal Reflux Disease?
title_full_unstemmed How to Make the Right Choice of Proton Pump Inhibitor for Patients with Gastroesophageal Reflux Disease?
title_short How to Make the Right Choice of Proton Pump Inhibitor for Patients with Gastroesophageal Reflux Disease?
title_sort how to make the right choice of proton pump inhibitor for patients with gastroesophageal reflux disease
topic gastroesophageal reflux disease
parietal cell
proton pump inhibitors
pantoprazole
bioavailability
drug-drug interactions
url https://www.gastro-j.ru/jour/article/view/770
work_keys_str_mv AT yuvevsyutina howtomaketherightchoiceofprotonpumpinhibitorforpatientswithgastroesophagealrefluxdisease